Recent Updates
Recently added Catalysts
DBVT Positive Sentiment Score: 70/100

DBV Technologies to Report Third Quarter 2023 Financial Results and Business Update

Friday, October 27, 2023 2 min read
Key Takeaway: DBV Technologies will hold a conference call on October 31, 2023, to discuss its third quarter financial results and provide a business update. The call will be accessible via teleconference and a live webcast will also be available. DBV Technologies is focusing on its Viaskin technology, which offers a novel method for immunotherapy via the skin. This indicates ongoing developments in their food allergy programs, including Viaskin Peanut.

Market Sentiment Analysis

POSITIVE FACTORS

  • DBV Technologies is set to provide a business update which suggests progress.
  • The upcoming conference call reflects the company's transparency and engagement with investors.
  • DBV's innovative Viaskin technology has broad potential applications in immunotherapy.

Full Press Release Details

Montrouge, France, October 27, 2023
DBV Technologies to Report Third Quarter 2023 Financial Results and Business Update
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Tuesday, October 31st, at 5:00 p.m. ET to review third quarter 2023 financial results and provide a business update.
Interested participants may access this call via the below teleconferencing numbers and asking to join the DBV Technologies call:
United States: 1-844-481-2866
International: 1-412-317-1859
A live webcast of the call will be available on the Investors & Media section of the Company’s website: https://www.dbv-technologies.com/investor-relations/. A replay of the presentation will also be available on DBV’s website after the event.
About DBV Technologies
DBV Technologies is developing Viaskin™, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT™, and is DBV Technologies’ method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBV Technologies’ food allergies programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies has global headquarters in Montrouge, France, and North American operations in Basking Ridge, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).
katie.matthews@dbv-technologies.com
angela.marcucci@dbv-technologies.com
Viaskin and EPIT are trademarks of DBV Technologies.

Attachments

Frequently Asked Questions

When will DBV Technologies report their Q3 2023 financial results?

DBV Technologies will report their Q3 2023 financial results on October 31st.

How can I access the DBV Technologies conference call?

You can access the call by calling 1-844-481-2866 in the U.S. or 1-412-317-1859 internationally.

Where can I find the live webcast for the DBV call?

The live webcast can be found on the Investors & Media section of DBV's website.

What technology is DBV Technologies developing?

DBV Technologies is developing Viaskin™, an investigational platform for immunotherapy.

What is the focus of DBV Technologies' food allergies programs?

The focus is on the clinical trials of Viaskin Peanut for food allergic patients.

Tags: DBVT Viatris Investor Conferences Healthcare Viaskin immunotherapy food allergies financial results
Last updated: Oct 27, 2023